CLAY AGEE: Open Payments
NPI 1194201277 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,783 in 78 payments from 20 companies in 2025. Trend: 2023 $780 · 2024 $1,220 · 2025 $1,783
Food & beverage: $1,759Education: $24
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $284 |
| Novo Nordisk Inc | 12 | $281 |
| Medtronic, Inc. | 4 | $183 |
| Amgen Inc. | 10 | $144 |
| BETA BIONICS, INC. | 5 | $143 |
| Corcept Therapeutics | 6 | $120 |
| Xeris Pharmaceuticals, Inc. | 4 | $87 |
| Abbott Laboratories | 4 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $71 |
| Tandem Diabetes Care, Inc. | 3 | $62 |
Products named: Ozempic, MINIMED 780G, iLet Bionic Pancreas, MOUNJARO, Korlym, ZEPBOUND, EVENITY, GVOKE HYPOPEN.
Industry payments across AL — which companies pay providers there.
